Pharmaceutical maker Pfizer announced on Nov. 13 that it had completed its $10 billion acquisition of Metsera, ending a convoluted bidding war for the clinical-stage obesity biotech company.
Pfizer purchased all outstanding shares of Metsera stock at $65.60 per share, an enterprise valuation of about $7 billion, with additional contingent value right (CVR) payments of $20.65 per share that are tied to Metsera hitting certain clinical and regulatory milestones.
